COLLPLANT BIOTECHNOLOGIES LT CLGN
SHS NEW · Common Stock · CUSIP M2R51X116
- SectorHealth care
- IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $21.21.
Biggest buyers
| Roumell Asset Management, LLC | New | +563.0k |
| INVESTMENT MANAGEMENT OF VIRGINIA LLC | New | +530.1k |
| VILLERE ST DENIS J & CO LLC | New | +247.2k |
| FRIESS ASSOCIATES LLC | New | +235.1k |
| STATE STREET CORP | New | +176.5k |
| BENJAMIN F. EDWARDS & COMPANY, INC. | New | +64.6k |
| Weil Company, Inc. | New | +30.5k |
| RAYMOND JAMES & ASSOCIATES | New | +20.8k |
| CITADEL ADVISORS LLC | New | +13.0k |
| FNY Investment Advisers, LLC | New | +4.0k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Sagy Ami 13G · passive investor no change · filed 2026-10-08 | 5.7% |
Insider purchases and sales in Q2 2021
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2021.
Holders, Q2 2021
| Manager | Shares | Change |
|---|---|---|
| Roumell Asset Management, LLC 13.95% of their portfolio | 563.0k $11.9m | New |
| INVESTMENT MANAGEMENT OF VIRGINIA LLC 2.16% of their portfolio | 530.1k $11.2m | New |
| VILLERE ST DENIS J & CO LLC 0.28% of their portfolio | 247.2k $5.2m | New |
| FRIESS ASSOCIATES LLC 1.88% of their portfolio | 235.1k $5.0m | New |
| STATE STREET CORP 0.00% of their portfolio | 176.5k $3.7m | New |
| BENJAMIN F. EDWARDS & COMPANY, INC. 0.07% of their portfolio | 64.6k $1.4m | New |
| Weil Company, Inc. 0.33% of their portfolio | 30.5k $646.0k | New |
| RAYMOND JAMES & ASSOCIATES 0.00% of their portfolio | 20.8k $441.0k | New |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 13.0k $276.0k | New |
| ACT CAPITAL MANAGEMENT, LLC 0.08% of their portfolio | 7.5k $160.0k | First filing |
| FNY Investment Advisers, LLC 0.03% of their portfolio | 4.0k $84.0k | New |
| UBS Group AG 0.00% of their portfolio | 2.0k $43.0k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 597 $13.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 150 $3.0k | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |